At the beginning of the new year, the Department of Industry and Information Technology of Guangdong Province announced the 2022 list of “Specialized, Refined, Distinctive, and Innovative” SMEs. Guangzhou DiQi Pharmaceuticals Co., Ltd., as an outstanding representative of innovative pharmaceutical high-tech enterprises, was successfully selected and recognized as a Guangdong Provincial “Specialized, Refined, Distinctive, and Innovative” SME!

The concept of “Specialized, Refined, Distinctive, and Innovative” enterprises originated in 2011 as a collaborative initiative by multiple government departments—including the National Development and Reform Commission, Ministry of Industry and Information Technology, Ministry of Science and Technology, and Ministry of Finance—to cultivate outstanding small and medium-sized enterprises (SMEs). This program focuses on fostering SMEs that are innovation-driven, specialized in niche markets, hold significant market share, and demonstrate superior quality and efficiency. This honor fully affirms and highly recognizes DiQi Pharmaceuticals Co., Ltd.'s achievements in innovative sustained-release formulations, novel controlled-release formulations, biodegradable excipients, and related fields. It signifies that DiQi Pharmaceuticals Co., Ltd. has reached the industry's highest standards in technological capabilities, product quality, market potential, and multiple other aspects.

“Professionalization”Leveraging robust R&D capabilities, DiQi Pharmaceuticals Co., Ltd. focuses on exploring diverse drug delivery technologies. By optimizing drug delivery behavior, we reduce blood concentration fluctuations, minimize toxic side effects, and enhance patient compliance.

“Exquisite”Leveraging advanced design concepts and sophisticated formulation technologies, DiQi Pharmaceuticals Co., Ltd. has established an independent innovation technology platform. Through this platform, the company has developed a series of innovative sustained-release formulations, including microspheres, implants, and in-situ gels—complex, high-end formulations.

“Special”Based on extensive experience accumulated in R&D, manufacturing, regulatory affairs, and clinical trials, DiQi Pharmaceuticals Co., Ltd. has established a globally leading “high-end formulation innovation technology platform” and a customized “high-end specialty excipient” platform. These platforms have built multiple industry barriers for DiQi's products, resolving the bottleneck issue of reliance on imported high-end excipients.

“Innovation-driven”After years of refinement and innovation, DiQi Pharmaceuticals Co., Ltd has successfully developed six cGMP-compliant biodegradable polylactic acid copolymers, becoming the world's first company with dual registration in both China and the United States. The once-every-four-weeks “Risperidone Microspheres for Injection” utilizing this excipient, along with the lenalidomide sustained-release tablets developed using gastric retention technology, are both globally pioneering products that have obtained clinical approval in both China and the United States.

On the path of future development, DiQi Pharmaceuticals Co., Ltd will forge ahead with determination, steadfastly pursuing a path of “Professionalization， Exquisite, Special, and innovation”: further refining core technologies, accelerating the development of innovative products, and continuously leading technological innovation in the industry. Ultimately, we will realize our corporate vision of “developing and manufacturing high-quality, effective, long-acting, and highly compliant medicines that are affordable for the general public.”